Vancouver, September 2, 2020 (GLOBE NEWSWIRE) – BetterLife Pharma Inc.(“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company, announced that Dr.Eleanor Fish will continue to play a key role on the company’s Scientific Advisory Board after being appointed a member of the Canadian government’s COVID-19 Working Group in popularity for her experience in infectious diseases.
Dr. Fish is a world-renowned, comprehensive scientist who focuses on interferon activity opposed to a variety of viruses, adding SARS-CoV-2, SARS, Ebola and Zika.Fish will continue to advise the company’s existing and long-term clinical programs, adding its studies and progression strategy for AP-003, a patent-pending interferon a2b inhalation formula (IFNa2b) as an imaginable cure opposed to COVID-19.
She is the leader of a recent article published on Friday, May 15, 2020 in Frontiers of Immunology entitled “Interferon-2b Treatment for COVID-19”.In this study, the course of the disease was evaluated in a cohort of 77 people.other coVID-19 people entered Union Hospital, Tongji Medical College, Wuhan, China, between January 16 and February 20, 2020.
According to the authors’ knowledge, the effects presented in the study were the first to recommend the curative efficacy of IFN-a2b versus COVID-19 disease.
Warning note
The Company does not explicitly or implicitly make Altum’s AP-003 or any other product have the ability to remove, cure or involve COVID-19 (or SARS-2 coronavirus) at this time.
For more information, visit www.blifetherapeutics.com.
Contact Ahmad Doroudian, Managing Director Email: [email protected] Phone: 604-221-0595
Dost Mustaq, BDA International Investor Relations Contact: [email protected] Phone: 646-679-4321